Inflammation-inhibiting compounds

Details Inflammation-inhibiting compounds Inflammation-inhibiting compounds

2011-08-23

2011-08-23

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

08003608

ABSTRACT:
The present invention relates to the use of a compound of the formula Lys-X where X is a hydroxyl group, an amino group, alkoxy, Pro or Pro-Thr, or of a pharmaceutically acceptable salt thereof, for the treatment of inflammations. The invention also relates to the use of αMSH for inducing tolerance.

REFERENCES:
patent: 5614520 (1997-03-01), Kondo et al.
patent: 5939394 (1999-08-01), Fleming et al.
patent: 6117896 (2000-09-01), Qabar et al.
patent: 6245790 (2001-06-01), Hattori et al.
patent: 0 934 924 (1999-08-01), None
patent: 2 784 028 (2000-04-01), None
patent: WO88/00833 (1988-02-01), None
patent: WO 89/09226 (1988-03-01), None
patent: WO 89/09226 (1989-08-01), None
patent: WO89/09226 (1989-10-01), None
patent: WO96/23490 (1996-08-01), None
patent: WO96/27371 (1996-09-01), None
patent: WO 97/45117 (1997-12-01), None
What is Psoriasis? http://www.skincarephysicians.com/psoriasisnet/whatis.ht.
Mesri EA., “Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma.Blood,” Jun. 15, 1999;93(12):4031-3.
Portanova JP, et al, “Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo,” J Exp Med. Sep. 1, 1996;184(3):883-91.
Kalden DH, et al “Mechanisms of the antiinflammatory effects of alpha-MSH. Role of transcription factor NF-kappa B and adhesion molecule expression,” Ann N Y Acad Sci. Oct. 20, 1999;885:254-61.
Uehara Y, et al “The dipeptide Lys-Pro attenuates interleukin-1 beta-induced anorexia,” Peptides. Mar.-Apr. 1993;14(2):175-8.
Rajora N, et al, “Alpha-MSH modulates experimental inflammatory bowel disease,” Peptides. 1997;18(3):381-385.
Merck Manual Colitis Docuiment Name Merck(2010) found at http://www.merckmanuals.com/home/search.html?qt=colitis&qp=%2Bsite%3Awww%2Emerckmanuals%2Ecom+%2Burl%3A%2Fhome+%2Durl%3Aprint%2F+%2Durl%3Aindex%2F+%2Durl%3Aresources%2Fpronunciations+%2Durl%3Amultimedia+2F+%2Durl%3A%2Fhome%2Fau+%2Durl%3A%2Fhome%2Fag+&charset=utf8&la=en&start=0.
Oluyomi, A.O., et al., “Antinociceptive activity of peptides related to interleukin-1β-(193-195), Lys-Pro-Thr” European Journal of Pharmacology 1994; 258: 131-138.
Database CA Online, Chemical Abstracts Service, Columbus, Ohio, US; Suetsugu, Maseru et al, “Skin conditioners containing lysine derivatives,” retrieved from STN, Database accession No. 132:339047 HCA, XP002205557.
Database WPI Week 200033, Derwent Publications Ltd., London, GB; AN 2000-382026, XP002208222 & JP 2000 128726 A (Shiseido Co. Ltd.), May 9, 2000, Zusammenfassung.
Database WPI, Section Ch, Week 200057, Derwent Publications Ltd., London, GB; Class B07, AN 2000-602052, XP002208223—& WO 00 54750 A (Starchenko D A); Sep. 21, 2000, Zusammenfassung.
Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US; 1992 Palmieri G., et al., “Clinical and Immunological Effects of a Lysine Arginine Association in Atopic Dermatitis,” Database accession No. PREV199293081020, XP002205558, Zusammenfassung.
Himmi, E. H., et al., “Regulatory role of a peptide from the second constant domain of immunoglobulin G—II. In vitro effect on granuloma formation aroundS. mansonieggs,” Int. J. Immunopharmac. 1985; 7(2): 231-237.
Patent Abstracts of Japan, vol. 1998, No. 01; Jan. 30, 1998 & JP 09 249535 A (Honen Corp.), Sep. 22, 1997, Zusammenfassung.
Database CA Online, Chemical Abstracts Service, Columbus, Ohio, US; Terai, M., “Antibacterial, low-irritation cosmetics,” retrieved from STN, Database accession No. 127:336470 HCA, XP002236549, Zusammenfassung.
Database WPI, Week 199802, Derwent Publications Ltd., London, GB; AN 1998-011903, XP002236550 & JP 09 255518 A (Noevir KK), Sep. 30, 1997, Zusammenfassung.
Patent Abstracts of Japan, vol. 1998, No. 01, Jan. 30, 1998, & JP 09 255518 A (Noevir Co Ltd), Sep. 30, 1997, Zusammenfassung. .
Hiltz, M. E., et al., “Anti-Inflammatory Activity of α-MSH (11-13) Analogs: Influence of Alteration in Stereochemistry,” Peptides 1991; 12: 767-771.
Macaluso, A., et al., “Antiinflammatory Influences of α-MSH Molecules: Central Neurogenic and Peripheral Actions,” J Neurosci 1994;14(4): 2377-2382.
Richards, D. B., et al., “Effect of α-MSH 11-13 (Lysine-Proline-Valine) on Fever in the Rabbit,” Peptides 1984; 5: 815-817.
Beers, M.H., et al., “The Merck Manual of Diagnosis and Therapy,” 1999, Merck Research Laboratories, Whitehouse Station, NJ, XP002208945.
Thews, G., et al., “Anatomie, Physiologie und Pathophysiologie des Menschen,” 1991, WVG, Stuttgart XP002236548.
Vuitton, D., “The ambiguous role of immunity in echinococcosis: protection of the host or of the parasite?” Acta Tropica 2003; 85: 119-132.
International Search Report for PCT Application No. PCT/EP02/01323 prepared by the European Patent Office, issued on Apr. 29, 2003.
Klement et al.IκBα Deficiency Results in a Sustained NF-κB Response and Severe Widespread Dermatitis in Mice, Molecular and Cellular Biology, May 1996, p. 2341-2349.
Kwon et al.Insulin-like Growth Factor II Induces Interluekin-6 Expression via NF-κB Activation in Psoriasis, Biochemical and Biophysical Research Communications 278, 312-317 (2000).
Chen et al.RAG2-/-, IκBα Chimeras Display a Psoriasisform Skin Disease, J. Invest Dermatol 115:1124-1133, 2000.
Schmidt K.N.Anti-Psoriatic Drug Anthralin Activates Transcripton Factor NFκB in Murine Keratinocytes, The Journal of Immunology, 1996, 156:4514-4519.
Robert et al.Inflammatory Skin Diseases, T-Cells, and Immune Surveilance, The New England Journal of Medicine 341(24), 1817-1828, 1999.
Wirtz S, Neufert C, Weigmann B and Neurath F; Chemically Induced Mouse Models of Intestinal Inflammation. Nature Protocols vol. 2 No. 3. 2007 541-546.
Elson C.O, Sartor R.B., Tennyson G.S. and Riddel R H.; Experimental Models of Inflammatory Bowel Disease. Gastroenterology 1995:109:1344-1367.

Affiliated with

Also associated with

Rating

Inflammation-inhibiting compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inflammation-inhibiting compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inflammation-inhibiting compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2665516